| LDP-02 (Millenium). | |
| | |
MedLine Citation:
|
PMID: 11566006 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Millennium (formerly LeukoSite) and Genentech are developing LDP-02, a humanized monoclonal antibody to the alpha4beta7 integrin receptor on leukocytes, for potential use in the treatment of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis [274580]. LeukoSite intended to develop iv and sc formulations of LDP-02 for acute IBD [315156]. In December 1997, Genentech entered into a collaboration with LeukoSite to develop and commercialize LDP-02 for the treatment of IBD [275395], [279420]. A phase II SBIR grant was awarded to LeukoSite in September 1996. The US $750,000 grant was used to develop LDP-02 and to conduct preclinical tests on the antibody for the treatment of IBD [218689]. In February 1999, Lehman Brothers predicted the drug had a 10% probability of reaching market. Assuming a successful launch, Lehman Brothers analysts estimated peak sales would occur in 2011 with sales at that time of US $250 million [319225]. |
| | |
Authors:
|
J K Marshall |
Related Documents
:
|
9723046 - Treatment of facial telangiectases with the diode-pumped frequency-doubled q-switched n... 21774986 - Do production patterns influence the processing of speech in prelinguistic infants? 23289596 - A novel method of collection of saliva for estimation of steroid levels in extremely pr... 7453466 - Cryocauterization in the treatment of subglottic hemangioma in infants. 3985136 - Developmental and nutritional determinants of pregnancy outcome among teenagers. 3288866 - Prevention of necrotizing enterocolitis in low-birth-weight infants by iga-igg feeding. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in investigational drugs (London, England : 2000) Volume: 2 ISSN: 1472-4472 ISO Abbreviation: Curr Opin Investig Drugs Publication Date: 2001 Apr |
Date Detail:
|
Created Date: 2001-09-21 Completed Date: 2001-12-04 Revised Date: 2011-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 100965718 Medline TA: Curr Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 502-4 Citation Subset: IM |
Affiliation:
|
Department of Medicine, McMaster University, Hamilton, Ontario, Canada. marshallj@mcmaster.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / adverse effects, metabolism, therapeutic use* Clinical Trials as Topic Colitis, Ulcerative / therapy* Crohn Disease / therapy* Humans Integrins / immunology* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Integrins; 0/LDP-02 monoclonal antibody; 0/integrin alpha4beta7 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inflammatory mediators as therapeutic targets in acute pancreatitis.
Next Document: ALX-0600 (NPS Allelix Corp).